BioLineRx Discloses Abstract On Pilot Study Data From Phase 2 Combination Clinical Trial Evaluating Motixafortide In First-Line Pancreatic Cancer At American Society of Clinical Oncology 2024 Annual Meeting

5/24/24 7:02:58 AM ET

$BLRX

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $BLRX alert in real time by email

New analysis of biopsy samples demonstrated a significant increase in CD8+ T-cell density in tumors from all 11 patients treated
7 of 11 patients in the pilot phase experienced a partial response, with 6 confirmed; 10 of 11 patients experienced disease control
Poster Presentation on Saturday, June 1, 2024 in Chicago, Illinois

Get the next $BLRX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$BLRX

Date	Price Target	Rating	Analyst

More analyst ratings

BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA® (motixafortide) through Gamida Cell Ltd.
– BioLineRx to receive $10 million upfront payment from Ayrmid Ltd. (parent company of Gamida Cell) plus up to $87 million in commercial milestones, as well as royalties on net sales ranging from 18% to 23% – – BioLineRx retains rights to develop and commercialize motixafortide in solid tumors, including PDAC – – BioLineRx received $9 million equity investment from certain funds managed by Highbridge Capital Management, LLC to support company's pipeline and expansion – – Transactions enable significant reduction in BioLineRx's operational expenses and debt, and allow the company to focus on development activities in areas of high unmet need in oncology and rare diseases – – BioLineRx will
11/21/24 6:30:00 AM ET
$BLRX
Biotechnology: Pharmaceutical Preparations
Health Care
BioLineRx to Report Third Quarter 2024 Results on November 25, 2024
Management to Hold Conference Call at 8:30 a.m. EST TEL AVIV, Israel, Nov. 20, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it will release its unaudited financial results for the third quarter ended September 30, 2024 on Monday, November 25, 2024, before the U.S. markets open. The Company will host a conference call at 8:30 a.m. EST featuring remarks by Philip Serlin, Chief Executive Officer. To access the conference call, please dial +1-888-281-1167 from the U.S. or +972-3-918-0685 internationally. A live webcast and a replay of the call can
11/20/24 7:19:00 AM ET
$BLRX
Biotechnology: Pharmaceutical Preparations
Health Care
BioLineRx Reports Second Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates
- Secured APHEXDA® formulary placement among top 80 transplant centers representing ~37% of stem cell transplant procedures performed, surpassing stated goal for quarter; on-track to reach goal of ~60% by end of Q4 - - Doubled the number of centers ordering APHEXDA during the second quarter - - Entered into clinical trial agreement with St. Jude Children's Research Hospital to evaluate motixafortide for hematopoietic stem cell mobilization for gene therapies in sickle cell disease - - Management to host conference call today, August 15, at 8:30 am EDT - TEL AVIV, Israel, Aug. 15, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company purs
8/15/24 7:00:00 AM ET
$BLRX
Biotechnology: Pharmaceutical Preparations
Health Care

BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA® (motixafortide) through Gamida Cell Ltd.
– BioLineRx to receive $10 million upfront payment from Ayrmid Ltd. (parent company of Gamida Cell) plus up to $87 million in commercial milestones, as well as royalties on net sales ranging from 18% to 23% – – BioLineRx retains rights to develop and commercialize motixafortide in solid tumors, including PDAC – – BioLineRx received $9 million equity investment from certain funds managed by Highbridge Capital Management, LLC to support company's pipeline and expansion – – Transactions enable significant reduction in BioLineRx's operational expenses and debt, and allow the company to focus on development activities in areas of high unmet need in oncology and rare diseases – – BioLineRx will
11/21/24 6:30:00 AM ET
$BLRX
Biotechnology: Pharmaceutical Preparations
Health Care
BioLineRx to Report Third Quarter 2024 Results on November 25, 2024
Management to Hold Conference Call at 8:30 a.m. EST TEL AVIV, Israel, Nov. 20, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it will release its unaudited financial results for the third quarter ended September 30, 2024 on Monday, November 25, 2024, before the U.S. markets open. The Company will host a conference call at 8:30 a.m. EST featuring remarks by Philip Serlin, Chief Executive Officer. To access the conference call, please dial +1-888-281-1167 from the U.S. or +972-3-918-0685 internationally. A live webcast and a replay of the call can
11/20/24 7:19:00 AM ET
$BLRX
Biotechnology: Pharmaceutical Preparations
Health Care
BioLineRx Announces Oral Presentation on Data from Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease at ASH 2024
- Findings suggest motixafortide alone, and in combination with natalizumab, could support the collection of the large number of stem cells required by gene therapies for sickle cell disease within a single apheresis cycle - - Data from proof-of-concept study shows that motixafortide was safe and well tolerated - - Oral presentation at ASH 2024 on Saturday, December 7, 2024 in San Diego, California - TEL AVIV, Israel and WALTHAM, Mass., Nov. 5, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that an abstract including the initial results from a Phase
11/5/24 9:00:00 AM ET
$BLRX
Biotechnology: Pharmaceutical Preparations
Health Care

BioLineRx Discloses Abstract On Pilot Study Data From Phase 2 Combination Clinical Trial Evaluating Motixafortide In First-Line Pancreatic Cancer At American Society of Clinical Oncology 2024 Annual Meeting

Chat with this insight

Recent Analyst Ratings for
$BLRX

$BLRX
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

HC Wainwright reiterated coverage on BioLineRx with a new price target

HC Wainwright resumed coverage on BioLineRx

HC Wainwright & Co. reiterated coverage on BioLine Rx with a new price target

$BLRX
Financials

Live finance-specific insights

$BLRX
Press Releases

Fastest customizable press release news feed in the world

$BLRX
SEC Filings

BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA® (motixafortide) through Gamida Cell Ltd.

BioLineRx to Report Third Quarter 2024 Results on November 25, 2024

BioLineRx Reports Second Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates

BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA® (motixafortide) through Gamida Cell Ltd.

BioLineRx to Report Third Quarter 2024 Results on November 25, 2024

BioLineRx Announces Oral Presentation on Data from Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease at ASH 2024

SEC Form 6-K filed by BioLineRx Ltd.

SEC Form 424B5 filed by BioLineRx Ltd.

SEC Form 6-K filed by BioLineRx Ltd.

$BLRX
Market Insights

Live Market Insights

HC Wainwright & Co. Reiterates Buy on BioLine Rx, Maintains $21 Price Target

BioLineRx Announces Multi-Center Phase 1 Trial Sponsored By St. Jude Children's Research Hospital To Evaluate Motixafortide For CD34+ Hematopoietic Stem Cell Mobilization For Gene Therapy Applications In Sickle Cell Disease

HC Wainwright & Co. Reiterates Buy on BioLine Rx, Maintains $21 Price Target

$BLRX
FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

FDA Approval for APHEXDA issued to BIOLINERX, LTD.

$BLRX
Leadership Updates

Live Leadership Updates

$BLRX
Large Ownership Changes

This live feed shows all institutional transactions in real time.

BioLineRx Appoints Tami Rachmilewitz, M.D., as Chief Medical Officer

BioLineRx Announces Appointment of Commercial Strategy and Operations Veteran Holly W. May as Chief Commercial Officer

SEC Form SC 13G/A filed by BioLineRx Ltd. (Amendment)

SEC Form SC 13G/A filed

SEC Form SC 13G/A filed

BioLineRx Discloses Abstract On Pilot Study Data From Phase 2 Combination Clinical Trial Evaluating Motixafortide In First-Line Pancreatic Cancer At American Society of Clinical Oncology 2024 Annual Meeting

Chat with this insight

Recent Analyst Ratings for $BLRX

$BLRX Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

HC Wainwright reiterated coverage on BioLineRx with a new price target

HC Wainwright resumed coverage on BioLineRx

HC Wainwright & Co. reiterated coverage on BioLine Rx with a new price target

$BLRX Financials

Live finance-specific insights

$BLRX Press Releases

Fastest customizable press release news feed in the world

$BLRX SEC Filings

BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA® (motixafortide) through Gamida Cell Ltd.

BioLineRx to Report Third Quarter 2024 Results on November 25, 2024

BioLineRx Reports Second Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates

BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA® (motixafortide) through Gamida Cell Ltd.

BioLineRx to Report Third Quarter 2024 Results on November 25, 2024

BioLineRx Announces Oral Presentation on Data from Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease at ASH 2024

SEC Form 6-K filed by BioLineRx Ltd.

SEC Form 424B5 filed by BioLineRx Ltd.

SEC Form 6-K filed by BioLineRx Ltd.

$BLRX Market Insights

Live Market Insights

HC Wainwright & Co. Reiterates Buy on BioLine Rx, Maintains $21 Price Target

BioLineRx Announces Multi-Center Phase 1 Trial Sponsored By St. Jude Children's Research Hospital To Evaluate Motixafortide For CD34+ Hematopoietic Stem Cell Mobilization For Gene Therapy Applications In Sickle Cell Disease

HC Wainwright & Co. Reiterates Buy on BioLine Rx, Maintains $21 Price Target

$BLRX FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

FDA Approval for APHEXDA issued to BIOLINERX, LTD.

$BLRX Leadership Updates

Live Leadership Updates

$BLRX Large Ownership Changes

This live feed shows all institutional transactions in real time.

BioLineRx Appoints Tami Rachmilewitz, M.D., as Chief Medical Officer

BioLineRx Announces Appointment of Commercial Strategy and Operations Veteran Holly W. May as Chief Commercial Officer

SEC Form SC 13G/A filed by BioLineRx Ltd. (Amendment)

SEC Form SC 13G/A filed

SEC Form SC 13G/A filed

Recent Analyst Ratings for
$BLRX

$BLRX
Analyst Ratings

$BLRX
Financials

$BLRX
Press Releases

$BLRX
SEC Filings

$BLRX
Market Insights

$BLRX
FDA approvals

$BLRX
Leadership Updates

$BLRX
Large Ownership Changes